The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.
Murthy Chavali, PhD
Advertisement
Murthy Chavali is Director of Clinical Development at Ocugen, Inc. He is an accomplished leader in drug discovery, research and development with over 20 years of experience in academic and pharmaceutical industry.
Articles by Murthy Chavali, PhD
Advertisement
Latest Updated Articles
Navigating the maze: Establishing novel end points for IRD trialsPublished: October 1st 2025 | Updated:
